Fibrogen 2025 Q2 Earnings Record Net Income and Strong Revenue Growth

Fibrogen (FGEN) reported its fiscal 2025 Q2 earnings on August 11, 2025, with strong results across revenue and net income. The company raised its full-year revenue guidance, reflecting confidence in its business operations and strategic initiatives.

Fibrogen’s total revenue for the second quarter of 2025 increased by 35.1% to $1.35 million, compared to $998,000 in the same period in 2024. This growth was driven by strong performance in the drug product segment, which accounted for $1.22 million of the total revenue. Additionally, the development and other revenue segment contributed $133,000 to the quarter’s earnings.

The company significantly improved its net income, narrowing losses to $1.88 per share in Q2 2025, compared to a loss of $3.89 per share in Q2 2024. Fibrogen’s net loss for the quarter was reduced to $7.60 million, a 51.1% improvement from $15.54 million in the prior-year period. Notably, this marked the highest net income for Fibrogen in 12 years.

Fibrogen’s stock price exhibited mixed performance in the short term. During the most recent trading day, the shares declined by 4.12%, but they surged by 20.78% over the full trading week and rose by 13.88% month-to-date.

Post-earnings price action analysis revealed a poor performance for a buy-and-hold strategy. Specifically, purchasing Fibrogen shares following a revenue increase and holding for 30 days returned -91.96% over the past three years, underperforming the benchmark by 137.66%. The strategy’s Sharpe ratio of -0.47 indicates significant risk exposure without meaningful returns.

CEO Thane Wettig highlighted key strategic priorities, including the sale of Fibrogen China to AstraZeneca, the advancement of FG-3246 for mCRPC, and the development of roxadustat for MDS-related anemia. The China sale is expected to streamline operations, pay off the term loan, and extend Fibrogen’s cash runway into 2028. Wettig noted the Phase II trial for FG-3246 would start in Q3 and that the company had aligned with the FDA on a pivotal Phase III trial for roxadustat.

Fibrogen raised its 2025 revenue guidance to a range of $6 million to $8 million, with total operating costs and expenses expected to be between $65 million and $75 million. The company anticipates submitting the Phase III roxadustat protocol by Q4 2025 and expects clinical milestones for FG-3246, including the initiation of the monotherapy trial in Q3 and top-line results for the FG-3246/enzalutamide combination trial in Q4 2025.

Additional News
Recent non-earnings related news includes a U.S. Department of Commerce announcement on new export controls, a global economic summit in New York featuring world leaders, and a major healthcare policy update from the U.S. FDA. These events are expected to influence Fibrogen’s strategic direction and regulatory landscape.